Hikma Pharmaceuticals reaffirms commitment to expanding access to overdose-reversal medicine naloxone at White House meeting

Press Release Corporate 6 June 2024

Hikma Pharmaceuticals reaffirms commitment to expanding access to overdose-reversal medicine naloxone at White House meeting

London 6 June 2024 – Hikma Pharmaceuticals in the US this week reaffirmed its longstanding commitment to expanding access to the opioid overdose-reversal medicine naloxone while participating with the Office of National Drug Control Policy (ONDCP) in a White House conversation on opioid reversal agents. 

ONDCP convened the June 4th White House meeting for an important pharmaceutical-industry dialogue about FDA-approved overdose prevention antagonists, including naloxone, and manufacturers’ critical role in expanding access to these medicines. This meeting follows ONDCP Director Dr. Rahul Gupta’s visit to Hikma’s manufacturing facility in Columbus, Ohio earlier this year. While visiting with Hikma, Dr. Gupta witnessed the production of naloxone and met with local harm reduction groups to learn about Hikma’s partnerships, donation programs and other efforts to address the opioid epidemic.

“As a manufacturer of multiple forms of opioid reversal agents, Hikma continues taking action to help address the opioid overdose epidemic,” said Dr. Hafrun Fridriksdottir, President of Hikma’s Generics business. “We are partnering with health care providers, non-profit organizations and the public health community to ensure naloxone is widely accessible to all who can benefit from it, including by donating more than 450,000 doses of naloxone over the last three years. We were honored to join Dr. Gupta, his colleagues and industry peers at the White House for this important conversation to advance our shared goal of saving lives through expanding access to overdose-reversal medicines like naloxone.” 

Hikma has a decades-long record of manufacturing and supplying naloxone and opioid use disorder (OUD) medicines. The company manufactures multiple forms and delivery methods of naloxone including generic injectable vials and prefilled syringes, and KLOXXADO® (naloxone 8mg) intranasal spray. 

Through its Hikma Community Health initiative, Hikma is partnering with those on the frontlines of the opioid public health emergency across the US to help expand access to naloxone, including by: 

• Donating more than 450,000 doses of KLOXXADO® and injectable naloxone to harm reduction groups, community organizations and others across the US. With the help of more than 40 donation partners, KLOXXADO® has been distributed for free in places it can have the biggest impact, including music festivals, downtowns and schools.

• Donating 50,000 vials of injectable naloxone in 2021 to members of Remedy Alliance – a leading supplier of naloxone to harm-reduction programs in the US – to help ease a nationwide shortage.

• Furthering our partnership with Remedy Alliance by providing the first and only private label, discounted naloxone injectable medicine made specifically for the harm-reduction community. As covered in The Washington Post, this partnership ensures supply and price are no longer barriers to this opioid overdose antidote to hundreds of harm reduction groups nationwide.

• Ensuring widespread access to KLOXXADO® by providing a Co-Pay Assistance Program for eligible individuals, further increasing access and decreasing out-of-pocket costs to this life-saving medication.

• Partnering with State Government and Community Programs to expand access to our naloxone portfolio and continuing to provide generic medications for the treatment of substance use disorder to patients and health care providers.

Download press release

This product has been approved for marketing in the United States by the US FDA. This product approval does not confer the right on Hikma, or any other party, to market this product outside the United States.